BioCentury
ARTICLE | Finance

CRISPR pigs

Why Biomatics, Arch co-led $38M series A for xenotransplantation play eGenesis

March 17, 2017 7:05 PM UTC

Drawn by CRISPR’s potential to address the organ transplant shortage with safer xenotransplants, Biomatics Capital Partners and Arch Venture Partners co-led a $38 million series A round for eGenesis Inc. intended to fund the company through preclinical proof of concept by YE19.

eGenesis raised the tranched round on March 16 with participation from Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising and Fan Ventures. Details on the tranches are undisclosed...